Bridging the gap between laboratory bench and hospital bedside

Canada stands to benefit from an integrated therapeutic pipeline approach to investments that combines expertise, skills training, biomanufacturing know-how, and private sector partnerships to deliver on the shared priority.

Our country is at the tipping point of paving a pathway for patients to access new treatment approaches in a timely manner and can support the development of novel immunotherapies needed to treat Canadian cancer patients during this fragile post-pandemic recovery, write John Bell and Stéphanie Michaud. Photograph courtesy of Unsplash

Opinion

BY JOHN BELL AND STéPHANIE MICHAUD

March 30, 2022

Canada has a long tradition of supporting fundamental cancer research, creating a world-class cadre of scientists and clinician-scientists making significant contributions to the fundamental understanding of cancer biology, genomics, and immunology. Unfortunately, we are plagued with a funding and e...

To keep reading, subscribe and become a political insider.

Only $7.76 a week for an annual subscription.

Enjoy unlimited website access and the digital newspaper.

Cancel anytime.

Already a Subscriber?

Get Weekend Point of View Newsletter

A round up of the past weekâ€™s opinion writers and columnists on Saturdays and Sundays.

By entering your email address you consent to receive email from The Hill Times containing news, analysis, updates and offers. You may unsubscribe at any time. See our privacy policy